

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	edoxaban
Brand Name	Lixiana®
Dosage Form(s)	15 mg, 30 mg and 60 mg tablets
Manufacturer	Servier Canada Inc.
Submission Type	New Submission
Use Reviewed	For stroke and blood clots prevention in atrial fibrillation, and for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)
Common Drug Review (CDR)	Yes, CDR recommended: to Reimburse with clinical criteria and/or conditions. Visit the CDR website for more details: www.cadth.ca/sites/default/files/cdr/complete/SR0500_complete_Lixiana-NVAF_Mar-23-17.pdf . www.cadth.ca/sites/default/files/cdr/complete/SR0499_complete_Lixiana_VTE_May_29_17_e.pdf .
Provincial Review	DBC now screens drug submissions under review by the Common Drug Review (CDR) to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision will be based on the CDEC recommendation and an internal review only. The DBC screened Lixiana® on October 3, 2016. The DBC advised that because edoxaban is similar to other direct oral anticoagulants (DOACs) used for stroke and blood clots prevention in atrial fibrillation, and for the treatment and prevention of DVT and PE, the Ministry may accept the CDEC's recommendation for edoxaban.
Drug Coverage Decision	Non-Benefit
Date	March 26, 2019
Reason(s)	Drug coverage decision is inconsistent with the CDEC recommendations. <ul style="list-style-type: none"> The drug was similar to or demonstrated some advantage over warfarin with respect to efficacy and safety. There were no direct comparison trials with other DOACs. Based on economic considerations and the submitted product price, the drug was not cost-effective and/or did not offer optimal value for money. The Ministry currently covers three other DOACs for stroke and blood clots prevention in atrial fibrillation, and two other DOACs for the treatment and prevention of DVT and PE. The CDR noted that there was no evidence to suggest that edoxaban meets a need that is not currently met by other DOACs.
Other Information	none

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.